Inspire Medical Systems (NYSE:INSP) Price Target Raised to $59.00

Inspire Medical Systems (NYSE:INSP) had its target price upped by Robert W. Baird from $54.00 to $59.00 in a report published on Tuesday morning, MarketBeat Ratings reports. They currently have a neutral rating on the stock.

A number of other equities analysts have also weighed in on INSP. Oppenheimer raised Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 target price on the stock in a research report on Tuesday. Zacks Research raised shares of Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research report on Monday, July 6th. Mizuho decreased their price target on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating for the company in a research note on Tuesday, May 5th. Stifel Nicolaus lowered their price objective on shares of Inspire Medical Systems from $70.00 to $65.00 and set a “buy” rating on the stock in a report on Tuesday, May 5th. Finally, Freedom Capital raised shares of Inspire Medical Systems to a “strong-buy” rating in a research note on Tuesday, June 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $68.00.

Inspire Medical Systems Trading Down 2.0%

Shares of NYSE INSP opened at $58.91 on Tuesday. The firm has a market capitalization of $1.70 billion, a P/E ratio of 12.75, a P/E/G ratio of 4.55 and a beta of 0.70. The firm’s 50-day moving average price is $47.26 and its 200-day moving average price is $54.48. Inspire Medical Systems has a 1-year low of $38.91 and a 1-year high of $147.03.

Inspire Medical Systems (NYSE:INSP) last issued its earnings results on Monday, August 3rd. The company reported $0.14 EPS for the quarter, beating the consensus estimate of ($0.24) by $0.38. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%.The company had revenue of $200.58 million during the quarter, compared to the consensus estimate of $194.72 million. The firm’s revenue for the quarter was down 7.6% compared to the same quarter last year. During the same period last year, the business posted $0.45 EPS. Inspire Medical Systems has set its FY 2026 guidance at 1.050-1.450 EPS. Equities research analysts forecast that Inspire Medical Systems will post 1.24 EPS for the current year.

Hedge Funds Weigh In On Inspire Medical Systems

Hedge funds have recently bought and sold shares of the company. CWM LLC grew its stake in shares of Inspire Medical Systems by 216.1% in the 4th quarter. CWM LLC now owns 354 shares of the company’s stock worth $33,000 after acquiring an additional 242 shares in the last quarter. EverSource Wealth Advisors LLC lifted its position in shares of Inspire Medical Systems by 1,115.4% during the first quarter. EverSource Wealth Advisors LLC now owns 632 shares of the company’s stock valued at $33,000 after purchasing an additional 580 shares in the last quarter. Havemeyer Place LP bought a new position in shares of Inspire Medical Systems during the fourth quarter valued at about $39,000. V Square Quantitative Management LLC purchased a new position in Inspire Medical Systems during the fourth quarter worth about $40,000. Finally, Smartleaf Asset Management LLC boosted its holdings in Inspire Medical Systems by 84.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock worth $42,000 after purchasing an additional 205 shares during the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.